TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07366866: A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of Gen

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 56 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,507,200

Rescue Site Savings

+$4,950,060

Unlock Full NCT07366866 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07366866 Rescue Dossier →